TMEM164

Across TCGA pan-cancer cohorts, TMEM164 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TMEM164 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher TMEM164 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMEM164 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

LSCC, LUAD, and GBM are the cancer types where TMEM164 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.563	1.000	.022	5	view →
LUAD	OS	Median	II,III,IV	0.481	1.000	.049	2	view →
GBM	OS	Median	All	0.916	0.565	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TMEM164–LSCC (DFS)

Open the LSCC breakdown →